Cover Image
市場調查報告書

急性呼吸窘迫症(ARDS):開發平台分析

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192441
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
急性呼吸窘迫症(ARDS):開發平台分析 Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 97 Pages
簡介

急性呼吸窘迫症(ARDS)是肺中具有彈性的小氣囊(肺泡)積留體液造成的。常見的根本原因有敗血症,吸入有害物質,嚴重肺炎,頭部和胸部的外傷等。徵兆與症狀有嚴重的呼吸急促,呼吸困難,異常快的呼吸,低血壓,精神混亂,極度的疲勞等。

本報告提供急性呼吸窘迫症(ARDS)的治療藥之開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

急性呼吸窘迫症(ARDS)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機別關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機別

開發治療藥的企業

  • Altor BioScience Corporation
  • Athersys, Inc.
  • Faron Pharmaceuticals Oy
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Histocell S.L.
  • Phylogica Limited
  • Serendex Pharmaceuticals A/S
  • Silence Therapeutics Plc
  • Therabron Therapeutics, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALT-836
  • BIO-10901
  • CG-367
  • Cyndacel-M
  • GSK-2586881
  • GSK-2862277
  • interferon beta-1a
  • molgramostim
  • Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders
  • Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension
  • PF-05285401
  • PYC-35
  • PYC-36
  • PYC-38
  • PYC-98
  • Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome
  • S-1229
  • SAN-101
  • Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders
  • Stem Cell Therapy for Inflammatory Lung Diseases
  • Stromal Cell Therapy for Acute Respiratory Distress Syndrome
  • Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8319IDB

Summary

Global Markets Direct's, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016', provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
  • The report reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Acute Respiratory Distress Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Respiratory Distress Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Acute Respiratory Distress Syndrome - Overview
    • Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis
    • Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies
    • Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Acute Respiratory Distress Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acute Respiratory Distress Syndrome - Products under Development by Companies
  • Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes
  • Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
    • Altor BioScience Corporation
    • Athersys, Inc.
    • Faron Pharmaceuticals Oy
    • FirstString Research, Inc.
    • GlaxoSmithKline Plc
    • Global Blood Therapeutics, Inc.
    • Hydra Biosciences, Inc.
    • Phylogica Limited
    • S-Evans Biosciences, Inc.
    • Savara Inc.
    • Silence Therapeutics Plc
  • Acute Respiratory Distress Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALT-836 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-10901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-11006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBT-440 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2586881 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2862277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HC-067047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon beta-1a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-0011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PYC-35 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PYC-36 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PYC-38 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PYC-98 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-1229 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Respiratory Distress Syndrome - Dormant Projects
  • Acute Respiratory Distress Syndrome - Discontinued Products
  • Acute Respiratory Distress Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • May 25, 2016: First patient dosed in Savaras pivotal trial for PAP
      • Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation
      • Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS
      • Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome
      • Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP
      • Aug 09, 2015: Serendex to initiate first phase II clinical trial
      • Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November
      • May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
      • May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical's inhalable biological drug for treatment of severe pulmonary diseases
      • May 10, 2015: Positive topline data from Serendex phase I clinical trial
      • Feb 27, 2015: Serendex submits phase I application
      • Feb 13, 2015: Serendex partners up with leading German lung center
      • Jan 28, 2015: Serendex receives positive scientific advice from EMA
      • Jan 22, 2015: Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition
      • Dec 10, 2014: Serendex Registers First Sale Of Molgradex
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016
  • Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Global Blood Therapeutics, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by S-Evans Biosciences, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Savara Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Respiratory Distress Syndrome - Dormant Projects, H2 2016
  • Acute Respiratory Distress Syndrome - Dormant Projects (Contd..1), H2 2016
  • Acute Respiratory Distress Syndrome - Dormant Projects (Contd..2), H2 2016
  • Acute Respiratory Distress Syndrome - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016
  • Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top